Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA3 | P07451 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6198304 | 0.80 | PDCD1 (0.30) | PDCD1CD274 | |
| SCHEMBL10436530 | 0.77 | SLC6A4 (0.38) | PDCD1CD274SLC6A4CHRM2CHRM4 | |
| SCHEMBL2526143 | 0.77 | DYRK1A (0.36) | — | |
| SCHEMBL16956427 | 0.77 | SLC6A4 (0.37) | SLC6A4CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL509943 | 0.76 | CYP4F2 (0.38) | PDCD1CD274CHRM2CHRM4CHRM5 | |
| SCHEMBL15783792 | 0.73 | ACHE (0.44) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL24795533 | 0.73 | LPL (0.34) | — | |
| SCHEMBL1875659 | 0.73 | KDM1A (0.35) | — | |
| SCHEMBL30601262 | 0.73 | NPC1 (0.36) | — | |
| SCHEMBL30739381 | 0.73 | CHRNB2 (0.34) | CA12CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9498476-B2 | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine | ALBANY MOLECULAR RESEARCH, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150366864-A1 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | CURIA GLOBAL, INC. | 2015-12-24 | — | — | US | disclosed |
| US-9156812-B2 | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-13 | — | — | US | disclosed |
| US-20150191494-A1 | TETRAHYDROISOQUINOLINES AND INTERMEDIATES THEREFOR | ALBANY MOLECULAR RESEARCH, INC. | 2015-07-09 | — | — | US | disclosed |
| US-20140275101-A1 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | CURIA GLOBAL, INC. | 2014-09-18 | — | — | US | disclosed |
| WO-2014134388-A1 | PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-04 | — | — | WO | disclosed |
| US-8445494-B2 | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-21 | — | — | US | disclosed |
| US-8420811-B2 | Tetrahydroisoquinolines and intermediates therefor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-16 | — | — | US | disclosed |
| US-20130060027-A1 | TETRAHYDROISOQUINOLINES AND INTERMEDIATES THEREFOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-07 | — | — | US | disclosed |
| US-20110160220-A1 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | Bristol-Myers Squibb Company and Albany Molecular Research, Inc. | 2011-06-30 | — | — | US | disclosed |
| US-20110077400-A1 | PROCESSES FOR PREPARING TETRAHYDROISOQUINOLINES | Bristol-Myers Squibb Company and Albany Molecular Research, Inc | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366864-A1 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | HTR2C, SYNCRIP, SFPQ | PDCD1 1584/4885CD274 2253/4885SLC6A4 28/4885 |
| US-20130060027-A1 | TETRAHYDROISOQUINOLINES AND INTERMEDIATES THEREFOR | FARS2, TPH1, COQ8A | PDCD1 1823/4885CD274 2681/4885SLC6A4 104/4885 |
| US-20140275101-A1 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | HTR2C, SYNCRIP, SFPQ | PDCD1 1584/4885CD274 2253/4885SLC6A4 28/4885 |
| US-20150191494-A1 | TETRAHYDROISOQUINOLINES AND INTERMEDIATES THEREFOR | FARS2, TPH1, COQ8A | PDCD1 1823/4885CD274 2681/4885SLC6A4 104/4885 |
| US-20110077400-A1 | PROCESSES FOR PREPARING TETRAHYDROISOQUINOLINES | HTR2C, HTR3B, TPH2 | PDCD1 1603/4885CD274 3169/4885SLC6A4 112/4885 |
| US-20110160220-A1 | CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE | HTR2C, SYNCRIP, SFPQ | PDCD1 1584/4885CD274 2253/4885SLC6A4 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.